Baltimore Magazine recognizes Alan Shikani MD FACS as TOP DOC 2015

Baltimore, MD - November 2015 - Dr. Alan Shikani, Otolaryngologist (Ear, Nose & Throat Specialist) awarded TOP DOC for 2012, 2013 and 2015. Baltimore Magazine's prestigious list of physicians & specialists is compiled among their peers, and serves as a resource that Baltimore Magazine readers have trusted for 29 years. Over 10,000 physicians were surveyed, responses tabulated and results listed, among them Dr. Alan Shikani. This TOP DOC is an expert in all aspects of rhinology (diseases of the nose, sinuses, including sinus surgery and cosmetic rhinoplasty) and of Head and Neck Surgery.

Dr Shikani is the director of the Maryland Nose and sinus Rhinology Fellowship. Since 2006, fellows have some from different areas of the world and spent an entire year training in rhinology under Dr Shikani's tutelage.

About Dr. Alan Shikani:

Alan ShikaniAlan H. Shikani, MD, FACS, clinician, researcher, teacher and inventor is a most accomplished physician in the field of otolaryngology. Dr Shikani completed his residency and fellowship training at the Johns Hopkins department of Otolaryngology-Head and Neck Surgery (according to US News, Johns Hopkins is #1 Otolaryngology-Head and Neck Surgery program in the United States for more than 20 years). Dr Shikani serves as chief of the Division of Otolaryngology-Head and Neck Surgery of Union Memorial Hospital in Baltimore, chief of the Division of Otolaryngology-Head the and Neck Surgery at Good Samaritan Hospital. He is also the founder and director of the Maryland Nose and sinus Rhinology Fellowship.

Dr. Shikani has performed over 11,000 nasal procedures over a 28 year career, and is continuously striving to improve his surgical skills and the precision of his procedures. These procedures cover all aspects of nasal surgery, including endoscopic sinus surgery, balloon sinuplasty, septoplasty, radiofrequency coblation of the turbinates, cosmetic rhinoplasty, and snoring surgery. For more information, please contact Dr. Shikani at The Nose & Sinus Center (410) 321-1025 or 410-554 NOSE (6673).

Dr. Shikani was also named Top Doc in 2012 and 2013.

Alan Shikani, MD, Ear, Nose, and Throat Specialist, Receives Award from National Medical Society

Alexandria, VA - Alan Shikani, MD, of Baltimore, MD, will receive the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) Honors Award and will be recognized during the AAO-HNSF 2012 Annual Meeting & OTO EXPO at the Walter E. Washington Convention Center in Washington, DC, September 9 - 12. The AAO-HNS presents the Honors Awards to medical professionals in recognition of extensive meritorious service through the presentation of instructional courses, scientific papers, participation on any AAO-HNS/F committee or in an Academy leadership position. Dr. Shikani is currently at Maryland ENT in Baltimore, MD. Featuring more than 250 scientific research sessions, 445 posters, and more than 350 instruction course hours for attendees, the AAO-HNSF 2012 Annual Meeting & OTO EXPO is the largest gathering of otolaryngologists in the world.

About the AAO-HNS

The American Academy of Otolaryngology - Head and Neck Surgery (, one of the oldest medical associations in the nation, represents nearly 12,000 physicians and allied health professionals who specialize in the diagnosis and treatment of disorders of the ears, nose, throat, and related structures of the head and neck. The Academy serves its members by facilitating the advancement of the science and art of medicine related to otolaryngology and by representing the specialty in governmental and socioeconomic issues.

IFOS, South Korea

Dr. Shikani was invited to Seoul South Korea on June 1-5, 2013, by the International federation of Oto- Rhino-laryngological Societies, to be the Chair and Moderator of a seminar on "Topical Therapy for Chronic Rhinosinusitis" and also to be present their novel research paper on " In-Office Balloon Sinuplasty, the new Frontier for treatment of Nasal polyps" You can view these documents on the links below.

IFOS news Dr Shikani Chair

IFOS news Dr Shikani Moderator

Latest Technology

Dr. Shikani has made numerous inventions which are currently on the market and have to date improved the lives of countless ENT patients. Dr Shikani currently holds twenty patents in his name, either individually or as a co-inventor, and he has co-founded a bio-tech company start-up the Airway Company which manufactures speaking valves for tracheotomy patients. Dr Shikani has published numerous publications in peer review journals and books, and made numerous presentations in national and international meetings. He has developed a number of devices that are now widely used in field of otolaryngology (listed below).

The Shikani Middle Meatal Antrostomy Stent: While a resident at The Johns Hopkins Hospital, Dr Shikani invented a new sinus stent (the Shikani Middle Meatal Antrostomy Stent*) that is used to prevent adhesions following endoscopic sinus surgery. Adhesions are the most common complication of sinus surgery that causes sinusitis to recur). Thousands of patients worldwide have benefited from the Shikani Middle Meatal Antrostomy Stent.


*Shikani, A. : A New Middle meatal antrostomy Stent For Endoscopic Sinus Surgery. Laryngoscope. 104: 638-641, 1994

*Shikani A: A middle Meatal Antrostomy Stent for Pediatric Endoscopic Sinus Surgery Am J Rhinology 10 (4): 225-228, 1996

The Shikani Tracheotomy Speaking Valve: Tracheotomy patients, who otherwise may be unable to speak, are helped by the Shikani Tracheotomy Speaking Valve* to recover their ability to communicate and talk.. The valve requires less effort and more easily tolerated than any other speaking valve on the market. Dr Shikani is the founder of The Airway Company Inc., which mission is helping people breathe and improving the patients' quality of life.

*Shikani AH, French J, Siebens AA. New unidirectional airflow ball tracheostomy speaking valve. Otolaryngol Head Neck Surg. 2000 Jul;123(1 Pt 1):103-7.

The Shikani Tracheotomy Speaking Valve

The Shikani Tracheotomy Speaking Valve is named for Dr. Shikani's pioneering work in the field of voice disorders.

The Shikani Optical Stylet (SOS):

The Shikani Optical Stylet

The Shikani Optical Stylet (manufactured by Clarus Medical, Minnesota)

The Shikani Optical Stylet

Dr. Shikani using the Shikani Optical Stylet for intubation

Shikani Optical Stylet (SOS): The Shikani Optical Stylet* was designed 1999 as a malleable, fiberoptic stylet to be used for difficult intubations. The Clarus Shikani has become the cornerstone of the Clarus line of difficult airway devices, and a popular tool for physicians worldwide. Otolaryngologists, anesthesiologists and emergency physicians are using the Shikani Optical Stylet to provide immediate, clear visualization of the airway. The Stylet is especially helpful for difficult intubations and for correct placement of endotracheal tubes. Dr Shikani also invented a new method of intubation using the SOS, which allows doctors to intubate without any Macintosh laryngoscope blade, hence avoding the risk of injuring the lips, teeth or larynx.

The Shikani Seeing Stylet for difficult intubation in children: initial experience

*Shikani A: A New Scope-Stylet for Management of the Difficult Airway. Otolaryngol. Head Neck Surg., 120(1): 113-116, 1999.

The Shikani Technique of intubation with the Shikani Optical Stylet

Baltimore Ravens

As the official medical team of the Baltimore Ravens, the Union Memorial Hospital offers the region's best in sports medicine, doctors and services. In his position of chief of Otolaryngology-Head and Neck Surgery at Union Memorial Hospital, Dr Shikani is the Otolaryngologist of the Baltimore Ravens team. He has treated several of the Ravens NFL players and coaches.

However, our services are not only for top athletes! We offer you the same resources that we offer to some of the country's best athletes, and we are only a phone call away.

To reach the Maryland ENT Center, call (410) 554 4455 or (410) 554 NOSE (6673)

The Shikani-El Hibri Prize for Discovery & Innovation at Johns Hopkins

In 2014, Alan H. Shikani, MD, founder and president of the Maryland ENT Center, and Fuad El-Hibri, founder and chair of Emergent BioSolutions established the Shikani/El Hibri Prize for Discovery & Innovation at the Johns Hopkins Bloomberg School of Public Health (JHSPH). This annual $10,000 prize recognizes excellence in the laboratory sciences and discoveries that have the potential to significantly advance biomedical science and to translate into improvements to patient care or the public's health. "The Prize for Discovery and Innovation" explained Dr Shikani and Mr El-Hibri "demonstrates our commitment to the extraordinary faculty at JHSPH and to support young teachers-scholars who dedicate themselves to academic excellence and creative pursuit. Our hope is that the Shikani/El-HibriPrize will inspire others to want to make a difference and support the new generation of Hopkins researchers."

Inspired by the impact of the Johns Hopkins School's work in public health, his own academic connections with Johns Hopkins and his son's (Henry Shikani) degree in Molecular Microbiology and Immunology at the Bloomberg School of Public Health, Dr. Shikani felt motivated to support those researchers whose works caries the potential to translate critical knowledge of laboratory research into the clinic and public health.

Having founded Emergent BioSolutions, a global specialty biopharmaceutical company whose corporate mission is to protect and enhance life, Mr. El-Hibri has dedicated his life work to advancing public health. "Instilling in our youth the love for discovery and innovation will help ensure a steady stream of scientific leaders. We hope that investing in today's faculty and scholars will lead to identifying new cures and treatments for tomorrow."

Recipients of the Shikani/El Hibri Prize for Discovery & Innovation at Johns Hopkins include:

2014 Recipient

The 2014 recipient is Dr. Jiou Wang, from the Department of Biochemistry & Molecular Biology of the JHSPH for his work: A novel, unifying mechanism for the molecular pathogenesis of Amyotrophic Lateral Sclerosis (ALS,or Lou Gehrig's disease) and Fronto-Temporal Dementia (FTD). By analyzing the mutation's structure at the RNA and DNA levels and identifying the causes of interference with protein production in diseased cells, Wang's team found the probable root cause of ALS. This exciting work has recently been published in Nature: "C9orf72 nucleotide repeat structures initiate molecular cascades of disease. 2014 Mar 13;507(7491):195-200."

Scott Bailey
Jiou Wang
Department of Biochemistry & Molecular Biology

2015 Recipient

The 2015 recipient is Dr Scott Bailey, from the Department of Molecular Microbiology and Immunology and the Malaria Research Institute of the JHSPH for his work: Understanding the molecular mechanisms underlying the CRISPR-based system of bacterial immunity. Scott and his team were the first to fully reconstitute the E. coli CRISPR system in vitro, which enabled them to distinguish the biochemical steps involved in the identification and destruction of invading DNA (but not host DNA). They also determined the high-resolution structure of Cascade bound to a ssDNA target, a technical tour-de-force that provides a molecular blueprint for understanding the mechanisms of the CRISPR system. This exception la work was recently accepted for publication at the very prestigious journal Science: "Targeted Destruction, How the bacterial CRIPR immune system recognizes foreign DNA."

Scott Bailey
Dr Scott Bailey
Department of Molecular Microbiology and Immunology

2016 Recipient

The 2016 recipient is Dr. Andrew Pekosz, from the W. Harry Feinstone Department of Molecular Microbiology and Immunology of the JHSPH for his work: "Restricted replication of the live attenuated influenza A virus vaccine during infection of primary differentiated human nasal epithelial cells". One of the principle ways Dr Pekosz is contributing to our basic research efforts is through the use of primary human nasal epithelial cell (hNEC) cultures to study influenza virus replication and cellular responses to infection. This culture system is capable of discerning changes in the replication of various clinical isolates in a way that no other standard cell culture system is capable of, which is allowing JH-CEIRS to be able to differentiate different influenza virus isolates as to their fitness for spreading in the human population and will become an important tool to assess the "pandemic potential" - the threat a particular animal influenza virus carries for becoming a human pathogen - of a number of animal influenza viruses that are being isolated at other CEIRS facilities Dr. Pekosz's knowledge of influenza biology and his use of hNEC cultures are indispensable for the JH-CEIRS work we are moving forward in a way that bridges clinical studies, basic research and public health. His studies of LAIV replication in hNEC cultures fit perfectly into this description. He is providing molecular and mechanistic insights into LAIV replication using a novel culture system and his research could lead to better influenza vaccines, which are sorely needed. This exciting work was recently published in Vaccine: 33 (2015) 4495-4504.

Andrew Pekosz
Andrew Pekosz PhD
Co-Director, Johns Hopkins Center of Excellence in Influenza Research and Surveillance (JH-CEIRS)
Director, Center for Emerging Viruses and Infectious Diseases (CEVID)

Alan H Shikani MD, FASC is elected President of the Crowe Johns Hopkins Alumni ENT Society, 2015-2017

Crowe Society

The Johns Hopkins Crowe Society

The purpose of the Johns Hopkins Crowe Society is:

  1. To assist The Johns Hopkins residents in training in the Department of Otolaryngology-Head and Neck Surgery at the Johns Hopkins University and to achieve excellence by supporting their research and educational activities.
  2. To advance the art and science of otolaryngology by promoting educational, scientific, and community functions.
  3. To encourage fellowship among the alumni and faculty of the department of Otolaryngology-Head and Neck Surgery of the Johns Hopkins University.